AIMS: Tumour-associated macrophages (TAM) have been reported to be regulators of progression in various human cancers. We evaluated the prognostic relevance of TAM in a large series of patients with papillary renal cell carcinoma (PRCC). METHODS AND RESULTS: The impact of TAM on cancer-specific survival (CSS) in 177 patients with PRCC was assessed using the Kaplan-Meier method and log-rank test. A multivariate Cox regression analysis was performed with respect to CSS. The presence of TAM was noted in 112 of 177 (63%) tumours and was associated statistically significantly with favourable pathological parameters, including low pathological T stage, node-negative tumours, low tumour grade, absence of vascular invasion and papillary subtype (all P < 0.05), respectively. Five-year CSS probabilities for patients with TAM-positive tumours were 93.5%, compared with 72.5% in patients with TAM-negative tumours, respectively (P < 0.001). Multivariate analysis revealed node-positive tumours, distant metastases and UICC stage (I versus II-IV) as independent predictors of death from PRCC, whereas the presence of TAM was associated independently with favourable outcome (hazard ratio = 0.45, 95% confidence interval 0.24-0.84, P = 0.012). CONCLUSIONS: The presence of TAM was shown independently to reduce the risk of death from cancer by 55%. The presence of TAM should therefore become part of routine pathology reporting in PRCC.
AIMS: Tumour-associated macrophages (TAM) have been reported to be regulators of progression in various humancancers. We evaluated the prognostic relevance of TAM in a large series of patients with papillary renal cell carcinoma (PRCC). METHODS AND RESULTS: The impact of TAM on cancer-specific survival (CSS) in 177 patients with PRCC was assessed using the Kaplan-Meier method and log-rank test. A multivariate Cox regression analysis was performed with respect to CSS. The presence of TAM was noted in 112 of 177 (63%) tumours and was associated statistically significantly with favourable pathological parameters, including low pathological T stage, node-negative tumours, low tumour grade, absence of vascular invasion and papillary subtype (all P < 0.05), respectively. Five-year CSS probabilities for patients with TAM-positive tumours were 93.5%, compared with 72.5% in patients with TAM-negative tumours, respectively (P < 0.001). Multivariate analysis revealed node-positive tumours, distant metastases and UICC stage (I versus II-IV) as independent predictors of death from PRCC, whereas the presence of TAM was associated independently with favourable outcome (hazard ratio = 0.45, 95% confidence interval 0.24-0.84, P = 0.012). CONCLUSIONS: The presence of TAM was shown independently to reduce the risk of death from cancer by 55%. The presence of TAM should therefore become part of routine pathology reporting in PRCC.
Authors: Krzysztof M Krawczyk; Helén Nilsson; Roni Allaoui; David Lindgren; Michael Arvidsson; Karin Leandersson; Martin E Johansson Journal: Lab Invest Date: 2017-07-31 Impact factor: 5.662
Authors: Dominik A Barth; Ondrej Slaby; Christiane Klec; Jaroslav Juracek; Rares Drula; George A Calin; Martin Pichler Journal: Cancers (Basel) Date: 2019-10-17 Impact factor: 6.639
Authors: Maria A Smolle; Laurin Herbsthofer; Mark Goda; Barbara Granegger; Iva Brcic; Marko Bergovec; Susanne Scheipl; Barbara Prietl; Amin El-Heliebi; Martin Pichler; Armin Gerger; Florian Posch; Martina Tomberger; Pablo López-García; Julia Feichtinger; Claudia Baumgartner; Andreas Leithner; Bernadette Liegl-Atzwanger; Joanna Szkandera Journal: Oncoimmunology Date: 2021-03-11 Impact factor: 8.110